Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ7S | ISIN: FR0013481835 | Ticker-Symbol: 7V91
Frankfurt
26.04.24
21:41 Uhr
0,180 Euro
+0,006
+3,45 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VISIOMED GROUP Chart 1 Jahr
5-Tage-Chart
VISIOMED GROUP 5-Tage-Chart
RealtimeGeldBriefZeit
0,1700,20426.04.
Actusnews Wire
320 Leser
Artikel bewerten:
(2)

VISIOMED GROUP: Visiomed Group announces a great start of the year for its Smart Salem centers with a new footfall record in January

  • More than 13,504 tests performed in January 2024
  • An average of 614 tests per day
  • Volume growth of +34% compared with January 2023

Paris, February 1, 2024

VISIOMED GROUP (FR0013481835 - ALVMG), a group dedicated to innovative healthcare technologies and services, announces a new footfall record in January 2024 for its Smart Salem subsidiary.

Following a strong growth in 2023 (+41% in volume compared with 2022), Smart Salem confirms its excellent start of the 2024 financial year as it welcomed 13,504 people in January 2024 (+34% compared with January 2023).

The major strategic actions implemented by the Group to consolidate Smart Salem's growth (new centers, diversification of services and tests, strengthening of marketing and sales) are therefore confirming their very positive impact, and build great expectations for Visiomed Group's activities in Dubai in 2024.

Clément Pacaud, CEO of Visiomed Group, comments: "We are starting the new year at Smart Salem with a record month and records weeks and days. The Group intends to build on the hard work of our teams and this excellent performance to support our development strategy in the region."

Number of tests performed (by volume)January 2024January 2023Change
Jan-24/Jan-23
Medical Fitness segment13,25110,067+32%
Wellness Tests segment253n.a.n.a.
Total number of tests performed13,50410,067+34%

***

About VISIOMED GROUP

Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.

The Group now has focused its activities on the Middle East since 2021 and the acquisition of Smart Salem, the first digital medical analysis centre accredited by the Dubai Health Authority (DHA) in the United Arab Emirates, 100% owned by Visiomed Group.

Visiomed is also accelerating its development in the region with the creation of Smart Health, a joint venture that will lead the deployment of the Group's innovative centres in Saudi Arabia.

Based in Paris, Visiomed Group is listed on Euronext Growth (ALVMG). For more information, visit www.visiomed-group.com

CONTACTS

Jérôme FABREGUETTES LEIBFatou-Kiné N'DIAYE
Investor RelationsFinancial Press Relations
visiomed@actus.frfndiaye@actus.fr
Phone: +33 1 53 67 36 78Phone: +33 1 53 67 36 75

© Visiomed Group SA 2024. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: ym9wlpaclGibmZ1qY8aXa5eXmWmUxGWUa5TGlWhuaMjJbGxgnZeSb52ZZnFllWds
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-84026-alvmg-cp-record-affluence-ssmc-2024.02.01-veng.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2024 Actusnews Wire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.